Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

被引：0
|
作者：
Teofila Seremet
Yanina Jansen
Simon Planken
Hassan Njimi
Mélanie Delaunoy
Hakim El Housni
Gil Awada
Julia Katharina Schwarze
Marleen Keyaerts
Hendrik Everaert
Danielle Lienard
Véronique Del Marmol
Pierre Heimann
Bart Neyns
机构：
[1] Universitair Ziekenhuis Brussel,Department of Medical Oncology
[2] Vrije Universiteit Brussel (VUB),Department of Dermatology
[3] Hôpital Erasme,Department of Biomedical Statistics
[4] Université Libre de Bruxelles (ULB),Laboratory of Molecular Biology in Haemato
[5] Université Libre de Bruxelles (ULB),oncology
[6] LHUB-ULB,Department of Nuclear Medicine
[7] Hôpital Erasme,undefined
[8] Université Libre de Bruxelles (ULB),undefined
[9] Universitair Ziekenhuis Brussel,undefined
[10] Vrije Universiteit Brussel (VUB),undefined
来源：
Journal of Translational Medicine | / 17卷
关键词：
Translational research; Liquid biopsy; Circulating tumor DNA; Monitoring; Immunotherapy; Metastatic melanoma; BRAF/NRAS mutations monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
    Wagner, Nikolaus B.
    Lenders, Max M.
    Kuehl, Kathrin
    Reinhardt, Lydia
    Andre, Fiona
    Dudda, Milena
    Ring, Natalie
    Ebel, Chiara
    Staeger, Ramon
    Zellweger, Caroline
    Lang, Roland
    Paar, Michael
    Gussek, Philipp
    Richtig, Georg
    Stuermer, Suzan H.
    Kimeswenger, Susanne
    Oellinger, Angela
    Forschner, Andrea
    Leiter, Ulrike
    Weide, Benjamin
    Gassenmaier, Maximilian
    Schraag, Amadeus
    Klumpp, Bernhard
    Hoetzenecker, Wolfram
    Berking, Carola
    Richtig, Erika
    Ziemer, Mirjana
    Mangana, Johanna
    Terheyden, Patrick
    Loquai, Carmen
    Nguyen, Van Anh
    Gebhardt, Christoffer
    Meier, Friedegund
    Diem, Stefan
    Cozzio, Antonio
    Flatz, Lukas
    Roecken, Martin
    Garbe, Claus
    Eigentler, Thomas K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [42] Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment
    Flaus, Anthime
    Habouzit, Vincent
    de Leiris, Nicolas
    Vuillez, Jean-Philippe
    Leccia, Marie-Therese
    Simonson, Mathilde
    Perrot, Jean-Luc
    Cachin, Florent
    Prevot, Nathalie
    DIAGNOSTICS, 2022, 12 (02)
  • [43] Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
    Egeler, Mees
    Lai-Kwon, Julia
    Tissier, Renaud
    Fraterman, Itske
    Kuijpers, Anke
    Van Houdt, Winan
    Wilgenhof, Sofie
    Rao, Aparna
    Sandhu, Shahneen
    Lee, Rebecca
    Eriksson, Hanna
    van Leeuwen, Marieke
    de Ligt, Kelly
    van Akkooi, Alexander
    van de Poll-Franse, Lonneke
    EUROPEAN JOURNAL OF CANCER, 2024, 200
  • [44] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [45] Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy
    Acar, Caner
    Yuksel, Haydar cagatay
    Sahin, Gokhan
    Acar, Fatma Pinar
    Gunenc, Damla
    Karaca, Burcak
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [46] FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
    Dimitriou, F.
    Lo, S. N.
    Tan, A. C.
    Emmett, L.
    Kapoor, R.
    Carlino, M. S.
    Long, G., V
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 99 - 106
  • [47] Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma
    Bastholt, Lars
    Schmidt, Henrik
    Bjerregaard, Jon Kroll
    Herrstedt, Jorn
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 122 - 131
  • [48] Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients
    Dalle, Stephane
    Verronese, Estelle
    N'Kodia, Axelle
    Bardin, Christine
    Rodriguez, Celine
    Andrieu, Thibault
    Eberhardt, Anais
    Chemin, Gabriel
    Hasan, Uzma
    Le-Bouar, Myrtille
    Caramel, Julie
    Amini-Adle, Mona
    Bendriss-Vermare, Nathalie
    Dubois, Bertrand
    Caux, Christophe
    Menetrier-Caux, Christine
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [49] Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy
    Pozorski, Vincent
    Park, Yeonhee
    Mohamoud, Yusuf
    Tesfamichael, Dahlia
    Emamekhoo, Hamid
    Birbrair, Alexander
    Albertini, Mark R.
    Ma, Vincent T.
    PIGMENT CELL & MELANOMA RESEARCH, 2023, 36 (06) : 501 - 511
  • [50] Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab
    Vihinen, Pia P.
    Ramadan, Susan
    Vuoristo, Meri-Sisko
    Hernberg, Micaela
    Tyynela-Korhonen, Kristiina
    Skytta, Tanja
    Koskivuo, Ilkka
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Syrjanen, Kari
    Pyrhonen, Seppo
    MELANOMA RESEARCH, 2011, 21 (05) : 431 - 437
12345